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ABSTRACT
The dopamine D3 receptor (D3R), in the nucleus accumbens (NAc), plays an important role 
in alcohol reward mechanisms. The major neuronal type within the NAc is the GABAergic 
medium spiny neuron (MSN), whose activity is regulated by dopaminergic inputs. We 
previously reported that genetic deletion or pharmacological blockade of D3R increases 
GABAA α6 subunit in the ventral striatum. Here we tested the hypothesis that D3R-
dependent changes in GABAA α6 subunit in the NAc affect voluntary alcohol intake, by 
influencing the inhibitory transmission of MSNs. 
We performed in vivo and ex vivo experiments in D3 knockout (D3R -/-) mice and wild type 
littermates (D3R +/+). Ro 15-4513, a high affinity α6-GABAA ligand was used to study α6 
activity.
At baseline, NAc α6 expression was negligible in D3R+/+, whereas it was robust in D3R−/−; 
other relevant GABAA subunits were not changed. In situ hybridization and qPCR 
confirmed α6 subunit mRNA expression especially in the NAc. In the drinking-in-the-dark 
paradigm, systemic administration of Ro 15-4513 inhibited alcohol intake in D3R+/+, but 
increased it in D3R−/−; this was confirmed by intra-NAc administration of Ro 15-4513 and 
furosemide, a selective α6-GABAA antagonist. Whole-cell patch-clamp showed peak 
amplitudes of miniature inhibitory postsynaptic currents in NAc medium spiny neurons 
higher in D3R-/- compared to D3R+/+; Ro 15-4513 reduced the peak amplitude in the NAc of 
D3R-/-, but not in D3R+/+.
We conclude that D3R-dependent enhanced expression of α6 GABAA subunit inhibits 
voluntary alcohol intake by increasing GABA inhibition in the NAc.
Key words: dopamine D3 receptor; GABAA receptor; alpha6 subunit; ethanol; nucleus 
accumbens; Ro 15-4513
Chemical compounds studied in this article Ro 15-4513 (PubChem CID: 5081); SB 
277011A (PubChem CID: 75358288); Furosemide (PubChem CID: 3440)
Abbreviations: DID, drinking in the dark paradigm; DR, dopamine receptor; D1-5R, 
dopamine D1-5 receptor; GABA, gamma-aminobutyric acid; GABAARs, GABAA receptors; 
ISH, in situ hybridization; mIPSCs,  miniature inhibitory postsynaptic currents; MSN, 
medium spiny neuron; NAc, nucleus accumbens; PFC, prefrontal cortex; VTA, ventral 
tegmental area.
1. Introduction
Alcohol is the most widely used and abused of all psychoactive drugs. Despite its 
mechanism of action being still elusive, general consensus recognizes its major impact on 
the brain reward system. Repeated intake of ethanol induces alterations in the nucleus 
accumbens (NAc), a main component of the mesolimbic reward circuit [1], as several other 
drugs of abuse [2]. In this brain region more than 95% of the cells are GABAergic Medium 
Spiny Neurons (MSNs), whose activity is regulated by dopaminergic and glutamatergic 
inputs [3]. MSNs comprise three distinct cell subpopulations; one expressing dopamine 
D1-like receptors (D1R and D5R), a second one expressing dopamine D2-like receptors 
(D2R, D3R, D4R), and a small third one expressing both D1-like and D2-like receptors [4, 5]. 
GABAA receptors (GABAARs) in the NAc have been considered as a primary target for 
alcohol, and may be involved in voluntary alcohol consumption [6]; moreover, chronic 
alcohol intake alters GABAergic function in the NAc, which sustains behavioral addictive 
patterns [1, 6]. GABAAR is an heteromeric pentamer chloride channel assembled from a 
variety of subunits from the 19 known up to now, α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3 [7]. This 
lead to the formation of multiple isoforms that are likely to differ in their alcohol sensitivity 
[8]. This ionotropic receptor represents a major pharmacological target for many drugs, 
including benzodiazepines, barbiturates and ethanol. While GABA binds to an orthosteric 
site, these exogenous compounds (and some endogenous modulators) bind to allosteric 
sites, affecting the gating of the channel and/or the response to GABA [7]. Previous 
findings reported that GABAAR containing α6 subunit is particularly sensitive to alcohol; 
indeed, rats expressing the naturally occurring R100Q allelic variation of α6 exhibit a 
higher sensitivity to motor incoordination induced by moderate doses of ethanol [9] and 
avoid alcohol consumption [10]. This mutation was originally found in a selectively bred, 
alcohol-sensitive rat line [11], which also shows reduced voluntary acceptance of alcohol 
solutions [12]. Furthermore, the hypersensitivity to ethanol was also seen in tonic inhibitory 
currents mediated by the α6βδ-type GABAARs in cerebellar slices [13]. GABAergic MSNs 
receive dopaminergic inputs from the ventral tegmental area (VTA) [14]; activation of this 
circuitry, the dopaminergic mesolimbic pathway, is classically considered as responsible 
for the reward response to physiological (e.g. food intake, sexual activity) or pathological 
(drug of abuse) stimuli. Activation of D3R, highly expressed in the NAc, is involved in the 
control of alcohol consumption [15-17]. Indeed, either D3R gene deletion or D3R 
pharmacological blockade inhibit alcohol intake [15]. Because DRs and GABAARs are co-
localized in MSNs, both contributing to the control of NAc output [18], we hypothesized 
that some cross-talk may exist between D3R and GABAARs in the regulation of reward 
system. In this respect, we have already shown that genetic deletion or pharmacological 
blockade of D3R, by using the selective D3R antagonist SB 277011A, increases GABAA α6 
subunit expression in the ventral striatum [19]. Thus, this behavioral effect on alcohol 
intake might be linked with changed GABAA α6 subunit expression levels in the NAc, due 
to the D3R gene deletion or D3R pharmacological blockade by SB 277011A. Here, we 
tested the hypothesis that D3R-dependent changes in GABAA α6 subunit expression in the 
NAc affect the alcohol intake behavior, and, at the cell level, the electrical activity of MSNs, 
thereby influencing the inhibitory synaptic transmission in the NAc. To do so, we attempted 
to directly reveal GABAA α6 activity, by using Ro 15-4513, an imidazobenzodiazepine 
GABAA ligand exerting differential effects depending on the α subunit present in the 
GABAAR isoform, showing negative allosteric agonism with α1,2,3 and 5, but positive 
agonism with α4 and α6 [20, 21]. Interestingly, based on molecular docking analysis and 
ligand binding interactions, Ro 15-4513 has been proposed to compete with ethanol within 
a binding pocket involving α6 [22, 23]. More importantly, Ro 15-4513 has shown efficacy in 
reducing alcohol drinking in rodents [24, 25], but the detailed mechanisms of action have 
remained unknown. However, Ro 15-4513 may be considered a high affinity α6-GABAAR 
ligand, since its binding is obvious in a α6 rich brain structure, such as the cerebellum, 
while it is hardly detectable in the very same structure in α6 null mice [26]. 
2. Materials and methods
2.1. Animals
Mice D3R-/-, D3R+/- and D3R+/+ littermates (males, 8–12 weeks old) were individually 
housed, with free access to chow and water (except in the ethanol drinking procedures), in 
an air-conditioned room, with a 12-h light–dark cycle. Mice D3R-/- and D3R+/- were congenic 
after 10th–12th generation of back crossing into C57BL/6J mouse line [27]. All 
experiments were carried out according to the Directive 2010/63/EU and to the Institutional 
Animal Care and Use Committee of the University of Catania. 
2.2. Analysis of mRNA expression by real-time quantitative RT-PCR
NAc was freshly dissected out for real-time quantitative RT-PCR by using punches 
(bilateral) of 14-gauge on ice, held in ice-cold PBS solution and frozen on dry ice 
according to Koo et al. [18]. Total RNA was isolated by TRIzol (Invitrogen, Carlsbad, CA) 
from the brain tissues. Single-stranded cDNA was synthesized with Super-Script III 
(Invitrogen), by random priming. Aliquots of cDNA were amplified in parallel reactions with 
external standards at known amounts, using specific primer pairs for α6-GABAA subunit, 
D3R and GAPDH (reference gene). GAPDH levels did not differ among different groups 
and were not changed by alcohol exposure in the DID paradigm. Each PCR reaction (20 μl 
final volume), contained 0.5 mM primers, 1.6 mM Mg2+, and 1 X Light Cycler-Fast Start 
DNA Master SYBR Green I (Roche Diagnostics, IN). Amplifications were carried out in a 
Light Cycler 1.5 instrument (Roche Diagnostics). Quantification was obtained by the ΔCt 
comparative method. 
2.3. Drinking in the dark paradigm (DID)
The 4-hour version of the behavioral paradigm was used, as described by Rhodes et al. 
[28]. The procedure started 3h after lights off in the animal room; water bottles were 
replaced with graduated tubes with stainless steel drinking spouts containing 20% (v/v) 
ethanol (Sigma, St Louis, MO)  in tap water; this was done in home cages where animals 
were singly housed [28]; the ethanol tubes remained in place for 2 h. After the 2-h period, 
intakes were recorded, and the ethanol tubes were replaced with water tubes. This 
procedure was repeated on days 2 and 3. On day 4, the procedure was again repeated 
except that the ethanol tubes were left in place for 4 h, and intakes were recorded after 4 
h. 
2.4. In situ hybridization and [3H]Ro 15-4513 autoradiography 
The in situ hybridization (ISH) and [3H]Ro 15-4513 autoradiography were carried out as 
described earlier [29, 30]. The detailed protocols are reported in Supplemental Information 
section. 
2.5. Systemic administrations
Ro 15-4513 and SB 277011A hydrochloride were from Tocris (Ellisville, MO). Drugs were 
intraperitoneally (i.p.) injected. Ro 15-4513 (5 mg/kg) [31] was dissolved in 10% dimethyl 
sulfoxide whereas SB 277011A hydrochloride (10 mg/kg) [15, 19] was dissolved in saline. 
All drugs and their respective vehicles were injected in a volume of 10 ml/kg. In the DID 
paradigm, we first tested D3R+/+, D3R+/- and D3R -/- naïve (n = 8/10 per group). For 
pharmacological experiments with Ro 15-4513, we allocated D3R+/+ and D3R -/- mice to 4 
experimental groups: D3R+/+ treated with vehicle, D3R+/+ treated with Ro 15-4513, D3R-/-  
treated with vehicle and D3R-/- treated with Ro 15-4513 (n = 8/10 per group).
In another set of experiments, D3R+/+ and D3R-/- were randomly allocated to 3 experimental 
groups (n= 8/13 per group): D3R+/+ treated with SB277011A for 7 days before SB 277011A 
plus Ro 15-4513 during the DID procedure; D3R+/+ treated with Vehicle for 7 days before 
Vehicle plus Ro 15-4513 during the DID procedure and D3R+/+ treated with Vehicle for 7 
days before Vehicle plus Vehicle during the DID procedure. SB 277011A and Ro 15-4513 
were i.p. injected, respectively 1h and 15 minutes before DID. On day 4, animals were 
sacrificed 1 h after ethanol-drinking procedure and the brain tissues were taken. 
2.6. Intra-accumbens administrations
Ro 15-4513 and furosemide (Tocris) were dissolved in 10% dimethyl sulfoxide and 90% 
synthetic cerebrospinal fluid (CSF) [15, 19]. Cannulas were implanted as previously 
described (11). After anesthesia with tiletamine + zolazepam (60 mg/kg) and 
medetomidine (40 μg/kg), mice were implanted with a 26-gauge guide cannula into the 
NAc (coordinates from Bregma: anterior-posterior = + 1.42 mm, latero-lateral ± 0.75 mm to 
a depth of 4.1 mm). The cannulas were fixed to the skull with acrylic dental cement 
(RelyX™ Unicem). After 6–8 days recovery, drugs (10 nmol/mouse ) were bilaterally 
injected in a final volume of 1 μl over 1 min through infusion cannulas connected to a 
Hamilton microsyringe by a polyethylene tube. Ro 15-4513 was injected 15 minutes before 
the DID, whereas furosemide was injected 5 min before Ro 15-4513. Animals were 
handled gently to minimize stress during infusion. After the infusion procedure, the needle 
was left in place for another minute to allow diffusion. In the DID paradigm, mice were 
allocated to three experimental groups (n = 8/10 per group): D3R-/- / vehicle, D3R-/- / Ro 15-
4513, D3R-/- / furosemide + Ro 15-4513. After behavioral testing, a solution of 4% 
methylene blue was infused for histological localization of infusion cannulas.
2.7. Electrophysiology
For the preparation of brain slices, we followed the protocol described by Scala et al. [32], 
with minor modifications. The detailed protocol is reported in Supplemental Information 
section. The electrophysiological recordings were analyzed using the Clampfit 10.7 
software (Molecular Devices). A template was constructed using the “Event 
detection/create template” function, as described in [33], then, miniature inhibitory 
postsynaptic currents (mIPSCs) were detected using the “Event detection/template 
search” function. All the waveforms detected during a single recording using template 
analysis were averaged and amplitude, rise time and decay time calculated. 
2.8. Statistical analysis
Data are expressed as means ± standard deviation (SD). Statistical significance was 
assessed with the Student’s t test (when used, paired-t test has been indicated in the text), 
one- or two-way analysis of variance (ANOVA) and post hoc Newman-Keuls. The level of 
significance was set at 0.05. 
3. Results
3.1. Alcohol intake and GABAA α6 subunit expression
We previously reported that D3R-/- mice have low ethanol intake [15] and exhibit higher 
basal expression of GABAA α6 in the ventral striatum [19]. Here, we assessed whether a 
link exists between alcohol consumption and GABAA α6 subunit expression in the NAc. 
D3R-/- exhibited about 5-fold higher basal mRNA expression of α6 subunit as compared 
with D3R+/+in the NAc [main effect of genotype F (2, 14) = 9.447, P<0.01; post hoc: 
P<0.01], but not in the prefrontal cortex (PFC), while other relevant GABAA subunits were 
not changed (Fig.1 A-B). Based on these data, we compared D3R+/+, heterozygous D3R+/- 
and homozygous D3R-/- in the drinking-in-the-dark (DID) paradigm. As shown in Fig. 1C, 
D3R+/+exhibited obvious ethanol preference in DID paradigm on day 1, 2 and 3, whereas 
D3R-/- had significantly lower ethanol intake [main effect of day: F (3, 60) = 40.58, P<0.01; 
main effect of genotype F (2, 20) = 7.812, P<0.01; post hoc: P<0.01 and P<0.05]. D3R+/- 
showed alcohol intake similar to D3R+/+and, consistently, a low α6 expression in the NAc 
(Fig. 1D).  The lack of difference in ethanol intake on day 4 might be linked to the 4h-time 
window used instead of a 2h-time window (see Methods). Overall, these data suggest that 
there is a link between α6 mRNA expression and alcohol intake such that the high level of 
GABAA α6 subunit expression in the NAc is associated to reduced alcohol consumption. 
To precisely assess the spatial expression of α6 subunit in the brain of D3R+/+and D3R-/-, 
we carried out in situ hybridization (ISH) experiments and analyzed the results in a blinded 
manner. These experiments confirmed that, while heavily enriched in the cerebellar 
granule cell layer, significant α6 expression in the forebrain of D3R-/- occurred specifically in 
the NAc [P<0.05], being very low in the other examined brain areas (Fig. 2 A-D, Tab. S1-
S2). Furthermore, the expression of other relevant GABAA subunits was not changed in 
D3R-/- (Tab. S1-S2). Data obtained by ISH confirmed the qPCR data (Fig. 1 A-B). 
Autoradiography following incubation with a high 15 nM concentration of [3H]Ro15-4513 
showed a statistically significant increase of [3H]Ro15-4513 binding in the NAc [P<0.05] 
(Fig. 2 E-F). Ro 15-4513 binds at α6/4β3δ-type GABAA receptors with high affinity (KD ≈ 10 
nM) [21, 34], consistent with an increased expression of α6/4β3δ-type GABAA receptors in 
the NAc.
3.2. Alcohol antagonist Ro 15-4513 increased ethanol consumption in mice expressing 
GABAA α6 in NAc
Ro15-4513 was earlier named “alcohol antagonist” [35], because, in some studies, it 
inhibited alcohol intoxication, preference and self-administration in wild type rodents [31, 
36]. Therefore, based on ISH and [3H]Ro15-4513 binding data, we tested the hypothesis 
that Ro 15-4513 differently affects ethanol intake in mice expressing different levels of α6 
in the NAc. As shown in Fig. 3 A, systemic administration of Ro 15-4513 decreased 
voluntary ethanol intake in D3R+/+ [main effect of day F (3, 63) = 55.62, P<0.01; main effect 
of treatment F (1, 21) = 7.198, P<0.05; post hoc: P<0.05], but increased voluntary ethanol 
intake in D3R-/- (Fig. 3 B) [main effect of day F (3, 39) = 34.87, P<0.01; main effect of 
treatment F (1, 13) = 9.384, P<0.01; post hoc: P<0.05]. Worthy of note, D3R-/-, which 
normally show low preference for alcohol [15], following Ro 15-4513–treatment reached a 
level of ethanol consumption similar to that of D3R+/+. To gain stronger evidence of the 
specific role of D3R-dependent expression of α6 GABAA subunit in the NAc, we tested 
D3R-/- mice in the DID after intra-NAc administration of Ro 15-4513, with or without 
furosemide, an α6-GABAA receptor antagonist [37]. As shown in Fig. 3 C, intra-NAc 
administration of Ro 15-4513 increased voluntary ethanol intake in D3R-/- [main effect of 
treatment F (2, 13) = 22.31, P<0.001; main effect of days X treatment interaction F (6, 39) 
= 3.297 P<0.05, post hoc: P<0.05, P<0.01 and  P<0.001 vs vehicle]; the effect of Ro 15-
4513 injected in this brain area was blocked by pretreatment with furosemide [main effect 
of treatment F (2, 13) = 22.31, P<0.001; main effect of days X treatment interaction F (6, 
39) = 3.297, post hoc: P<0.001 vs furosemide+Ro 15-4513] (Fig. 3D). This result confirms 
that the increased expression of α6-GABAAR in the NAc has a key role in modulating the 
paradoxical effect of Ro 15-4513 in D3R-/- mice, ruling out potential off target and/or non-
specific effects of Ro 15-4513 (on other brain areas, because of intraNAc injection, and on 
other GABAA receptor isoforms, because of furosemide antagonism). Thus, the 
paradoxical response to Ro 15-4513 seen in D3R-/- is related to increased expression of -
GABAAR in the NAc, which also accounts for the low ethanol consumption observed in 
these mice, as mentioned above.  
Changes of GABAAR function induced by alterations in dopaminergic transmission may 
have clinical relevance, because a number of DR ligands are currently used to treat 
different neuropsychiatric disorders [38]. In this respect, consistent with data obtained in 
D3R-/- mice, we previously reported that chronic treatment with the selective D3R 
antagonist SB 277011A increases α6 expression in the ventral striatum and accelerates 
the appearance of tolerance to the anxiolytic effect of diazepam [19]. Here, to assess the 
functional relevance of the D3R/α6-GABAAR cross-talk, we treated D3R+/+with SB 277011A 
for 7 days, (10 mg/kg i.p. as done in [19]) before testing in the DID paradigm. As shown in 
Fig. 3D, pretreatment of D3R+/+ with SB 277011A for 7 days, which increased the 
expression of α6-GABAAR in the NAc (Figure S1), induced a paradoxical effect of Ro 15-
4513 on alcohol intake, similar to D3R-/- [main effect of days F (3, 108) = 31.59, P<0.001; 
main effect of treatment F (2, 36) = 19.34, post hoc: P<0.05, P<0.001 vs vehicle]. These 
data indicate that treatment with a D3R antagonist, sufficient to change the expression of 
α6-GABAAR in the NAc, determines changes in ethanol intake. 
3.3. D3R-/- mice exhibited Ro 15-4513-driven decrease of mIPSC amplitude in Medium 
Spiny Neurons 
To test the hypothesis that α6 subunit expression in the NAc shell, as seen in D3R-/- mice, 
modifies inhibitory transmission, we performed whole-cell patch-clamp recordings on 
GABAergic MSNs, which represent >95% of the cell population in this brain region, and 
recorded miniature inhibitory postsynaptic currents (mIPSCs). Analysis of the peak 
amplitudes of mIPSCs revealed a significant increase in D3R-/- compared to D3R+/+(Fig. 4; 
A-D; 38.58 ± 3.35 pA, n = 19 versus 29.51 ± 2.96 pA, n = 16; P<0.05). In contrast, there 
was no significant difference in mIPSC frequency (D3R-/-: 1.98 ± 0.30 Hz, D3R+/+: 1.77 ± 
0.26 ms) and mIPSC kinetics (Fig. 4 G, H; rise time, D3R-/-: 0.72 ± 0.06 ms; D3R+/+: 0.72 ± 
0.06 ms; decay time, D3R-/-: 16.96 ± 1.10 ms; D3R+/+: 16.14 ± 1.31 ms). Next, we tested 
the effects of Ro 15-4513 on mIPSCs in MSNs from D3R+/+and D3R-/-. Based on ISH and 
qPCR data, indicating that α6-GABAARs in the NAc are scarce in naïve D3R+/+mice and 
given the opposite effect of Ro 15-4513 treatment on ethanol intake observed in D3R-/- 
mice, we expected that Ro 15-4513 would have differential effects on mIPSCs. For this in 
vitro experiment we selected the 0.3 μM Ro 15-4513 concentration, because it completely 
antagonizes ethanol enhancement of α4β3δ-type GABAAR current [21]. As shown in Fig. 
4, bath application of 0.3 μM Ro 15-4513 did not significantly alter the frequency, rise time, 
decay time and amplitude of mIPSCs in D3R+/+ (n = 16; paired t test), but induced a 
significant reduction of amplitude in the NAc of D3R-/- (Figure 3; B-F; 38.58 ± 3.35 pA, 
versus 31.93± 3.03 pA, n = 19 P<0.05; paired t test) while frequency, rise time and decay 
time were not affected. These results suggest that the activity of α6-GABAAR in D3R-/- 
influences inhibitory synaptic transmission of MSN within NAc shell, possibly because α6 
expression, higher than in D3R+/+, is sufficient to generate a population of heteromeric 
GABAARs containing α1 and α6 [39]. 
4. Discussion
We found that increased expression of α6 GABAA subunit, induced by D3R deletion or 
pharmacological blockade, is associated to reduced alcohol intake and increased GABA 
inhibition in the NAc. We revealed GABAA α6 activity by using Ro 15-4513, both in terms 
of behavior (ethanol intake) as well as of neuronal excitability (electrophysiology) a GABAA 
ligand that exerts α6-dependent effects. Ro 15-4513 is considered a high affinity α6-
GABAAR ligand, since its binding is obvious in a α6 rich brain structure, such as the 
cerebellum, while it is hardly detectable in the very same structure in α6 null mice [26]. 
We previously reported that alcohol sensitization is linked to increased D3R expression 
induced by ethanol intake and is associated with the activation of RACK1/BDNF pathway. 
In fact, selective blockade of the TrkB, the receptor for BDNF, reverses stable intake of 
ethanol in WT mice and decreases D3R expression levels in their striatum, while it results 
ineffective in D3R-/- mice [15]. 
The α6 subunit came to the attention of the alcohol addiction studies following the 
identification of the R100Q mutation in the Sardinian non-ethanol-preferring rat line, 
suggesting a possible involvement of the GABAAR containing α6 subunit in the genetic 
predisposition to alcohol preference [10]. This mutation is associated with hypersensitivity 
to motor-impairing effects of ethanol and tonic inhibitory currents mediated by α6βδ-type 
GABAAR in cerebellar granule cells [8, 13]. Worthy of note, this mutation strongly 
increases diazepam effect on GABA-evoked currents [11]. Consistently, a model where 
the amino acidic residue at position 100 affects ethanol sensitivity in the GABAARs is part 
of the benzodiazepine ligand-binding pocket on the α6-subunit [19, 40]. Other studies have 
also described α6 polymorphisms that correlate to alcohol dependence in humans [41, 42]. 
Our observation that genetic deletion or pharmacological blockade of D3R increased 
GABAA α6 subunit expression in the ventral striatum [16], a brain structure involved in 
voluntary ethanol intake, provides a tool to study how the increased expression of α6 
subunit-containing receptors may affect alcohol intake. Indeed, some studies have 
evaluated the contribution of other GABAAR subunits, such as α4 and δ, but no data are 
available on the role of NAc GABAA α6 subunit in alcohol intake; this latter has only been 
studied for its involvement in the motor incoordination associated to alcohol, given its 
abundant localization in cerebellum granule cells.
Several studies, in the last two decades, have tried to elucidate how the subunit 
composition of different GABAARs determines their electrophysiological and 
pharmacological features (inhibitory currents, ligand binding), or, at the organism level, the 
animal behavior (anxiety, addiction, response to anxiolytics). While most studies have 
dealt with recombinant systems, such as Xenopus laevis oocytes injected either with 
cRNA coding for the different subunits [9, 21] or with cRNA coding for concatenated 
subunits [43], no studies had the opportunity to examine native systems, i.e. animals 
spontaneously and stably expressing specific subunits in defined CNS structures. 
Polymorphisms of α6 subunit have been found to be associated both to anxiety-related 
traits [44] and to benzodiazepine sensitivity in humans [45]. It is not yet known whether 
increased expression of α6 subunit containing GABAAR isoforms in brain areas that 
normally express negligible amounts of α6 produces different responses to GABA (i.e. 
different inhibitory currents) and/or to exogenous modulators. This might be due to the lack 
of in vivo systems with significant changes in α6 expression. Early studies with α6 subunit 
knockout mice [26, 46] remained inconclusive as it was later discovered that the knockout 
construct affected the expression of neighboring subunits in the GABAA gene cluster [47]. 
We took advantage of Ro 15-4513, because it has been proposed to compete with ethanol 
within a binding pocket involving α6 [23]. We expected a different effect of Ro 15-4513 in 
D3R+/+, which poorly express α6 in the NAc, versus D3R-/-, which robustly express α6. 
Indeed, we found an opposite effect of Ro 15-4513 in the two groups; in D3R+/+, the 
systemic administration of Ro 15-4513 reduced ethanol intake, presumably as a result of 
its action as a negative allosteric modulator in multiple GABAARs [21], where it would 
behave as an “ethanol antagonist” [23, 48].  Conversely, in D3R-/-, Ro 15-4513 
paradoxically increased ethanol intake, a surprising finding that might be explained in 
terms of differential modulation of the GABAAR containing α6 subunit by Ro 15-4513. 
These data were confirmed and validated by intra-NAc injection experiments, where the 
local administration of furosemide, a selective α6-GABAA receptor antagonist [37], 
completely blocked the effect of Ro 15-4513. 
The antagonism between Ro 15-4513 and ethanol might be more at the functional level, 
rather than at the binding level. While the reported affinity of Ro 15-4513 for α4 and α6 
containing GABAAR is quite similar in the nanomolar range [9, 21, 23], the effect on the 
GABA-dependent currents in cells expressing exclusively α4 or α6 subunits is not clear 
and might be quite different. This is consistent with the paradoxical activation of neurons 
by gaboxadol in a transgenic Thy1α6 mouse line, ectopically expressing the GABAAR α6 
subunit gene under the Thy-1.2 promoter [20]. We directly address this issue by 
measuring MSN mIPSCs in the NAc and their sensitivity to Ro 15-4513. Based on the 
above premises, we hypothesized that a change in GABAA α6 subunit expression would 
increase spontaneous mIPSCs and that Ro 15-4513 would inhibit mIPSCs in MSN from 
D3R-/-, robustly expressing α6, whereas it would be ineffective in α6-deficient MSNs from 
D3R+/+. The electrophysiological analysis of MSNs revealed a significant increase in 
mIPSC amplitude in D3R-/-, which expressed GABAAR containing α6 subunit in NAc, 
compared to D3R+/+. Accordingly perfusion with Ro 15-4513 induced a significant reduction 
of amplitude in the NAc of D3R-/-, but was ineffective in D3R+/+. This latter observation 
clearly indicates that the modulation of the GABAAR channel by Ro 15-4513 depends on 
the presence of α6 subunit and is consistent with the observation of opposite effects of this 
drug on ethanol intake in D3R+/+and D3R-/-. To precisely assess the spatial expression of 
α6 subunit in the brain of D3R+/+and D3R-/-, we carried out in situ hybridization (ISH) 
experiments. The systematic assessment of α6 expression in the CNS by ISH confirmed  
qPCR results, indicating that α6 expression in D3R-/- was restricted to a limited brain area, 
corresponding to the NAc. These results were reinforced also by autoradiography data 
obtained with [3H]Ro 15-4513. The fact that genetic or pharmacological manipulation of 
D3R induced changes in the GABAAR α6 subunit expression specifically in the NAc  is 
consistent with the leaving relatively unchanged other brain areas is not so surprisingly, 
considering that, at variance with D2R, restricted expression of D3R in this brain region t 
same structures where we observe increased α6 expression [49]. To the best of our 
knowledge, it is not known in detail how D3R controls GABAAR subunit mRNA expression; 
however, other studies have shown dynamic D3R-dependent down-regulation of 
GABAergic control over lateral/basolateral amygdala neurons [50], NAc [51] and 
hippocampus [52]. A direct dynamic interplay between metabotropic DA receptors and 
other ionotropic receptors in plasma membrane has been documented by single-molecule 
detection imaging and electrophysiology in live hippocampal neurons [53]. Furthermore, 
cell signaling downstream of D3R affects GABAARs in the NAc [51], but numerous other 
complex mechanisms may impact GABAARs trafficking [54] and deserve further studies to 
be elucidated. Finally, because these changes in GABAAR function can be related to 
dopaminergic transmission, they may assume further relevance in clinical situations, such 
as schizophrenia and Parkinson’s disease, where D3R are chronically blocked or 
stimulated by drug-treatments [38]. 
In conclusion, these data indicate that α6-containing GABAARs in the NAc play an 
important role in controlling alcohol intake by increasing GABAergic-inhibition in the MSNs. 
Because changes in α6-containing GABAARs are specifically induced in the NAc by D3R-
blockade, the interplay between DAergic and GABAergic transmission may present a 
novel relevant mechanisms in reinforcing properties of alcohol and other addictive drugs. 
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Figure Legends
Figure 1. Alcohol intake and D3R-dependent GABAA α6 subunit mRNA expression in the 
NAc. A and B, GABAAR α1, α2, α4, α6, γ2 and δ subunits mRNA expression in the 
nucleus accumbens (NAc) and in the prefrontal cortex (PFC) of wild type (D3R+/+) and D3R 
null mice (D3R-/-). Abundance of transcripts was assessed by qPCR (primer sequences are 
reported in Tab. S3). C and D, ethanol intake (in the drinking in the dark paradigm, DID) 
and 6 expression in wild type (D3R+/+) heterozygous (D3R+/-) and null mice (D3R-/-). DID 
was measured for 4 days, in mice with limited access (2h/day for 3 days and 4h the 4th 
day) to ethanol solution (20%). Abundance of transcripts in the NAc was assessed by 
qPCR after DID; expression level is given as mean fold changes relative to controls.  
*P<0.05, **P<0.01 vs. the corresponding control (D3R+/+,); one- or two-way ANOVA and 
Newman–Keuls post hoc test.  Each experimental group included 8-10 mice.
Figure 2. Expression of 6 GABAA subunit mRNA and [3H]-Ro 15-4513 binding in the NAc 
and Cerebellum of D3R+/+ and D3R-/- mice. A, B, C and D In situ hybridization (ISH) 
detection of 6; E, F, G and H, [3H]-Ro 15-4513 autoradiography. A, C, E and G show 
representative images.  B, D, F and H show average optical density, (expressed in 
arbitrary units); n=6-8 per group. *P < 0.05 vs. D3R+/+, unpaired t test.
Figure 3. Opposite effect of RO 15-4513 on alcohol intake, in D3R+/+ and D3R-/- (drink in 
the dark paradigm, DID). A and B, ethanol intake in D3R+/+ and D3R-/- intraperitoneally (i.p.) 
treated with vehicle (VEH) or Ro 15-4513 (5 mg/kg); C, ethanol intake in D3R-/- locally 
injected into the NAc with VEH, Ro 15-4513 (10 nmol/mouse) or furosemide (10 
nmol/mouse) plus Ro 15-4513; D, ethanol intake in D3R+/+ pretreated with VEH or the 
selective D3R antagonist, SB 277011A for 7 days (10 mg/kg, i.p.) plus Ro 15-4513 (5 
mg/kg, i.p.) over DID paradigm. 
Each experimental group included 8-13 mice. *P<0.05, **P<0.01, ***P<0.001 vs. vehicle 
(VEH). One- or two- way ANOVA and Newman–Keuls post hoc test.
Figure 4. NAc medium spiny neurons from D3R-/- mice exhibited increased GABAA 
inhibitory currents sensitive to Ro 15-4513. A and B, representative traces showing mIPSC 
recordings in slice from D3R+/+  and D3R-/- mice before and after treatment with Ro 15-4513 
(0.3 µM; in red). C, analysis of the peak amplitudes of mIPSCs; notice an increase in D3R-/- 
compared to D3R+/+ and a decrease following Ro 15-4513 application in D3R-/- only. D-F, 
cumulative frequency distributions for mIPSC amplitude in the experimental conditions 
shown in A and B. G-I, analysis of mIPSC frequency, rise time and decay time. 
*P<0.05, unpaired (D3R-/- vs. D3R+/+) or paired (pre- vs. post- Ro 15-4513) t test (D3R-/-, 
n=19; D3R+/+, n=16).
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Supplementary Information
Table S1. In situ hybridization (ISH) signals for GABAA ??1, ??2, ??4, ??6, γ2 and δ subunit 
mRNA in the prefrontal cortex from D3R+/+ and D3R-/- mice.
GABAA subunit ISH signal (D3R-/- over D3R+/+ ratio)
α1 0.92  0.02
α2 1.10  0.11
α4 0.80  0.07
α6 1.15  0.13
γ2 0.89  0.30
δ   0.83  0.17
Table S2. In situ hybridization (ISH) signals for GABAA ??1, ??2, ??4, ??6, γ2 and δ subunit 
mRNA in the hippocampus from D3R+/+ and D3R-/- mice.
GABAA subunit ISH signal (D3R -/- over D3R +/+ ratio)
α1 0.91  0.09
α2 1.19  0.13
α4 1.07  0.03
α6 1.20  0.10
γ2 0.96  0.26
δ   0.85  0.16
Table S3. Primers for Real-Time PCR















Figure S1. Pharmacological blockade of D3R counteracts alcohol intake and induced 
overexpression of GABAA 6 subunit in the NAc of D3R+/+. A and B, ethanol intake (DID) and 
6 expression in D3R+/+ treated with vehicle (VEH) or the selective D3R antagonist, SB 
277011A (10 mg/kg, i.p.) for 7 days. Each experimental group included 8-13 mice. *P<0.05, 
***P<0.001 vs. VEH; two-way ANOVA and Newman–Keuls post hoc test.  
Material and Methods
In situ hybridization
Air-dried slides were fixed in ice-cold 4% paraformaldehyde for 5 min. The sections were 
washed in 1 PBS at room temperature for 5 min, dehydrated in 70% ethanol for 5 min and 
stored in 95% ethanol at 4 °C until used. The antisense DNA oligonucleotide probe (Oligomer 
Oy, Helsinki, Finland) sequences were as follows: α6, 5’-CAG TCT CTC ATC AGT CCA AGT 
CAT-3’;  was complementary to the mouse GABAAR subunit mRNA sequence. Poly[35S]dATP 
(PerkinElmer Life and Analytical Sciences, Boston, MA) tails were added to the 3’-ends of the 
probes by deoxynucleotidyl transferase (Promega Corporation, Madison, WI). Unincorporated 
nucleotides were removed by Illustra ProbeQuant G-50 Micro Columns (Amersham 
Biosciences, Buckinghamshire, UK). Labelling efficiency (360,000 cpm/μl) was determined by 
a scintillation counter. The labeled probe was diluted to 0.06 fmol/μl of hybridization buffer 
consisting of 50% formamide and 10% dextran sulfate in 4X Saline Sodium Citrate (SSC). 
Nonspecific controls for the antisense probes were produced by adding 100-fold excess of 
unlabeled probes. The hybridization occurred under glass Menzel-Gläser coverslips (Thermo 
Fisher Scientific, Boston, MA) overnight at 42 °C. Finally, the slides were washed in 1X SSC 
at room temperature for 10 min, in 1X SSC at 55°C for 30 min, and 1X SSC, 0.1X SSC, 70% 
EtOH and 95% EtOH at room temperature for 1 min each. The slides were then air-dried and 
exposed with plastic [14C]-radioactivity standards (GE Healthcare) to BioMax MR films 
(Eastman Kodak Company, Rochester, NY). Films were scanned (Epson expression 1680 
Pro). Images were imported into the FIJI version of the free image processing software 
ImageJ. The [14C]-standards were exposed simultaneously with the brain sections as the 
reference. The hybridization values were converted to arbitrary optical density units. Non-
specific signal was subtracted to obtain the specific signal. All measurements were analyzed 
in blind.
[3H]Ro 15-4513 autoradiography 
Slides were pre-incubated in ice-cold 50 mM Tris–HCl buffer, pH 7.4, containing 120 mM 
NaCl for 15 min. The final incubation for basal [3H]Ro 15-4513 binding was performed in the 
pre-incubation buffer containing 15 nM [3H]Ro 15-4513 (23 Ci/mmol, PerkinElmer Life and 
Analytical Sciences) at 4 °C for 1 h. This high ligand concentration was aimed at estimating 
the receptor number rather than affinity. The non-specific binding was determined in the 
presence of 10 μM flumazenil. The sections were then washed in ice-cold pre-incubation 
buffer twice for 1 min, dipped in ice-cold distilled water, air-dried at room temperature and 
exposed with [3H]-plastic standards for 12  weeks (GE Healthcare) to Biomax MR films 
(Eastman Kodak). The films were scanned (Epson expression 1680 Pro) and binding density 
was expressed as arbitrary optical density units (FIJI IMAGE-J). The [3H]-standards were 
exposed simultaneously with the sections as the reference. Non-specific binding was 
subtracted to obtain the specific binding values. All data were analyzed in blind.
Electrophysiology
Animals were sacrificed by cervical dislocation. Brains were rapidly removed and placed in 
ice-cold cutting solution containing (in mM): TRIS-HCl 72, TRIZMA base 18, NaH2PO4 1.2, 
NaHCO3 30, KCl 2.5, glucose 25, HEPES 20, MgSO4 10, Na-pyruvate 3, ascorbic acid 5, 
CaCl2 0.5, sucrose 20. Slices (300 μm thick) were cut on a vibratome (VT1200S; Leica 
Microsystems, Germany) and immediately transferred to an incubation chamber held at 32°C 
and filled with a recovery solution containing (in mM): TRIS-HCl 72, TRIZMA base 18, 
NaH2PO4 1.2, NaHCO3 25, KCl 2.5, glucose 25, HEPES 20, MgSO4 10, Na-pyruvate 3, 
ascorbic acid 5, CaCl2 0.5, sucrose 20. After 30 min, slices were transferred to a second 
incubation chamber held at 32°C and filled with artificial cerebrospinal fluid (aCSF) containing 
(in mM): NaCl 124, KCl 3.2, NaH2PO4 1.2, MgCl2 1, CaCl2 2, NaHCO3 26, and glucose 10, pH 
7.4. During incubations, the chambers were continuously bubbled with 95% O2/5% CO2. 
Slices were equilibrated at room temperature for at least 45 min. Slices were then transferred 
to a submerged recording chamber constantly perfused with heated aCSF (32°C) and 
bubbled with 95% O2/5% CO2. Medium spiny neurons (MSNs) within the NAc shell subregion 
were identified with a 40X water-immersion objective on an upright microscope equipped with 
differential interface contrast optics under infrared illumination (BX5IWI, Olympus, Center 
Valley, PA) and video observation. Electrodes were made from borosilicate glass 
micropipettes (Warner Instruments, Hamden, CT) prepared with a P-97 Flaming-Brown 
micropipette puller (Sutter Instruments, Novato, CA). Patch pipettes had a resistance of 4-6 
MΩ when filled with an internal solution containing (in mM): CsCl 135, HEPES 10, EGTA 1.1, 
CaCl2 0.1; Mg-ATP 2.5, Na-GTP 0.25, phosphocreatine 5, pH 7.2. After establishing a 
gigaseal, the patch was broken by applying negative pressure to achieve a whole-cell 
configuration. A series resistance lower than 15 MΩ was considered acceptable, and 
monitored constantly throughout the entire recording. Neurons were held at -70 mV. 
Tetrodotoxin (TTX, 0.5 μM, Tocris),  D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5, 50 
μM, Tocris) and 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide 
(NBQX, 10 μM, Tocris) were applied to the bath to block action potential-mediated 
neurotransmitter release, NMDA and AMPA receptors, respectively. Ro 15-4513 (0.3 μM) was 
applied in the bath after 5-7 min of TTX, APV and NBQX perfusion. All recordings were 
carried out at least 10 min after application of any drug to the bath. Recordings were 
performed using a Multiclamp 700B/Digidata 1550A system (Molecular Devices, Sunnyvale, 
CA) and digitized at a 10,000 Hz sampling frequency.
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The dopamine D3 receptor (D3R), in the nucleus accumbens (NAc), plays an important role 
in alcohol reward mechanisms. The major neuronal type within the NAc is the GABAergic 
medium spiny neuron (MSN), whose activity is regulated by dopaminergic inputs. We 
previously reported that genetic deletion or pharmacological blockade of D3R increases 
GABAA α6 subunit in the ventral striatum. Here we tested the hypothesis that D3R-
dependent changes in GABAA α6 subunit in the NAc affect voluntary alcohol intake, by 
influencing the inhibitory transmission of MSNs. 
We performed in vivo and ex vivo experiments in D3 knockout (D3R -/-) mice and wild type 
littermates (D3R +/+). Ro 15-4513, a high affinity α6-GABAA ligand was used to study α6 
activity.
At baseline, NAc α6 expression was negligible in D3R+/+, whereas it was robust in D3R−/−; 
other relevant GABAA subunits were not changed. In situ hybridization and qPCR 
confirmed α6 subunit mRNA expression especially in the NAc. In the drinking-in-the-dark 
paradigm, systemic administration of Ro 15-4513 inhibited alcohol intake in D3R+/+, but 
increased it in D3R−/−; this was confirmed by intra-NAc administration of Ro 15-4513 and 
furosemide, a selective α6-GABAA antagonist. Whole-cell patch-clamp showed peak 
amplitudes of miniature inhibitory postsynaptic currents in NAc medium spiny neurons 
higher in D3R-/- compared to D3R+/+; Ro 15-4513 reduced the peak amplitude in the NAc of 
D3R-/-, but not in D3R+/+.
We conclude that D3R-dependent enhanced expression of α6 GABAA subunit inhibits 
voluntary alcohol intake by increasing GABA inhibition in the NAc.






























































Chemical compounds studied in this article Ro 15-4513 (PubChem CID: 5081); SB 
277011A (PubChem CID: 75358288); Furosemide (PubChem CID: 3440)
Abbreviations: DID, drinking in the dark paradigm; DR, dopamine receptor; D1-5R, 
dopamine D1-5 receptor; GABA, gamma-aminobutyric acid; GABAARs, GABAA receptors; 
ISH, in situ hybridization; mIPSCs,  miniature inhibitory postsynaptic currents; MSN, 































































Alcohol is the most widely used and abused of all psychoactive drugs. Despite its 
mechanism of action being still elusive, general consensus recognizes its major impact on 
the brain reward system. Repeated intake of ethanol induces alterations in the nucleus 
accumbens (NAc), a main component of the mesolimbic reward circuit [1], as several other 
drugs of abuse [2]. In this brain region more than 95% of the cells are GABAergic Medium 
Spiny Neurons (MSNs), whose activity is regulated by dopaminergic and glutamatergic 
inputs [3]. MSNs comprise three distinct cell subpopulations; one expressing dopamine 
D1-like receptors (D1R and D5R), a second one expressing dopamine D2-like receptors 
(D2R, D3R, D4R), and a small third one expressing both D1-like and D2-like receptors [4, 5]. 
GABAA receptors (GABAARs) in the NAc have been considered as a primary target for 
alcohol, and may be involved in voluntary alcohol consumption [6]; moreover, chronic 
alcohol intake alters GABAergic function in the NAc, which sustains behavioral addictive 
patterns [1, 6]. GABAAR is an heteromeric pentamer chloride channel assembled from a 
variety of subunits from the 19 known up to now, α1-6, β1-3, γ1-3, δ, ε, θ, π, ρ1-3 [7]. This 
lead to the formation of multiple isoforms that are likely to differ in their alcohol sensitivity 
[8]. This ionotropic receptor represents a major pharmacological target for many drugs, 
including benzodiazepines, barbiturates and ethanol. While GABA binds to an orthosteric 
site, these exogenous compounds (and some endogenous modulators) bind to allosteric 
sites, affecting the gating of the channel and/or the response to GABA [7]. Previous 
findings reported that GABAAR containing α6 subunit is particularly sensitive to alcohol; 
indeed, rats expressing the naturally occurring R100Q allelic variation of α6 exhibit a 
higher sensitivity to motor incoordination induced by moderate doses of ethanol [9] and 
avoid alcohol consumption [10]. This mutation was originally found in a selectively bred, 





























































solutions [12]. Furthermore, the hypersensitivity to ethanol was also seen in tonic inhibitory 
currents mediated by the α6βδ-type GABAARs in cerebellar slices [13]. GABAergic MSNs 
receive dopaminergic inputs from the ventral tegmental area (VTA) [14]; activation of this 
circuitry, the dopaminergic mesolimbic pathway, is classically considered as responsible 
for the reward response to physiological (e.g. food intake, sexual activity) or pathological 
(drug of abuse) stimuli. Activation of D3R, highly expressed in the NAc, is involved in the 
control of alcohol consumption [15-17]. Indeed, either D3R gene deletion or D3R 
pharmacological blockade inhibit alcohol intake [15]. Because DRs and GABAARs are co-
localized in MSNs, both contributing to the control of NAc output [18], we hypothesized 
that some cross-talk may exist between D3R and GABAARs in the regulation of reward 
system. In this respect, we have already shown that genetic deletion or pharmacological 
blockade of D3R, by using the selective D3R antagonist SB 277011A, increases GABAA α6 
subunit expression in the ventral striatum [19]. Thus, this behavioral effect on alcohol 
intake might be linked with changed GABAA α6 subunit expression levels in the NAc, due 
to the D3R gene deletion or D3R pharmacological blockade by SB 277011A. Here, we 
tested the hypothesis that D3R-dependent changes in GABAA α6 subunit expression in the 
NAc affect the alcohol intake behavior, and, at the cell level, the electrical activity of MSNs, 
thereby influencing the inhibitory synaptic transmission in the NAc. To do so, we attempted 
to directly reveal GABAA α6 activity, by using Ro 15-4513, an imidazobenzodiazepine 
GABAA ligand exerting differential effects depending on the α subunit present in the 
GABAAR isoform, showing negative allosteric agonism with α1,2,3 and 5, but positive 
agonism with α4 and α6 [20, 21]. Interestingly, based on molecular docking analysis and 
ligand binding interactions, Ro 15-4513 has been proposed to compete with ethanol within 
a binding pocket involving α6 [22, 23]. More importantly, Ro 15-4513 has shown efficacy in 
reducing alcohol drinking in rodents [24, 25], but the detailed mechanisms of action have 





























































ligand, since its binding is obvious in a α6 rich brain structure, such as the cerebellum, 





























































2. Materials and methods
2.1. Animals
Mice D3R-/-, D3R+/- and D3R+/+ littermates (males, 8–12 weeks old) were individually 
housed, with free access to chow and water (except in the ethanol drinking procedures), in 
an air-conditioned room, with a 12-h light–dark cycle. Mice D3R-/- and D3R+/- were congenic 
after 10th–12th generation of back crossing into C57BL/6J mouse line [27]. All 
experiments were carried out according to the Directive 2010/63/EU and to the Institutional 
Animal Care and Use Committee of the University of Catania. 
2.2. Analysis of mRNA expression by real-time quantitative RT-PCR
NAc was freshly dissected out for real-time quantitative RT-PCR by using punches 
(bilateral) of 14-gauge on ice, held in ice-cold PBS solution and frozen on dry ice 
according to Koo et al. [18]. Total RNA was isolated by TRIzol (Invitrogen, Carlsbad, CA) 
from the brain tissues. Single-stranded cDNA was synthesized with Super-Script III 
(Invitrogen), by random priming. Aliquots of cDNA were amplified in parallel reactions with 
external standards at known amounts, using specific primer pairs for α6-GABAA subunit, 
D3R and GAPDH (reference gene). GAPDH levels did not differ among different groups 
and were not changed by alcohol exposure in the DID paradigm. Each PCR reaction (20 μl 
final volume), contained 0.5 mM primers, 1.6 mM Mg2+, and 1 X Light Cycler-Fast Start 
DNA Master SYBR Green I (Roche Diagnostics, IN). Amplifications were carried out in a 






























































2.3. Drinking in the dark paradigm (DID)
The 4-hour version of the behavioral paradigm was used, as described by Rhodes et al. 
[28]. The procedure started 3h after lights off in the animal room; water bottles were 
replaced with graduated tubes with stainless steel drinking spouts containing 20% (v/v) 
ethanol (Sigma, St Louis, MO)  in tap water; this was done in home cages where animals 
were singly housed [28]; the ethanol tubes remained in place for 2 h. After the 2-h period, 
intakes were recorded, and the ethanol tubes were replaced with water tubes. This 
procedure was repeated on days 2 and 3. On day 4, the procedure was again repeated 
except that the ethanol tubes were left in place for 4 h, and intakes were recorded after 4 
h. 
2.4. In situ hybridization and [3H]Ro 15-4513 autoradiography 
The in situ hybridization (ISH) and [3H]Ro 15-4513 autoradiography were carried out as 
described earlier [29, 30]. The detailed protocols are reported in Supplemental Information 
section. 
2.5. Systemic administrations
Ro 15-4513 and SB 277011A hydrochloride were from Tocris (Ellisville, MO). Drugs were 
intraperitoneally (i.p.) injected. Ro 15-4513 (5 mg/kg) [31] was dissolved in 10% dimethyl 
sulfoxide whereas SB 277011A hydrochloride (10 mg/kg) [15, 19] was dissolved in saline. 
All drugs and their respective vehicles were injected in a volume of 10 ml/kg. In the DID 
paradigm, we first tested D3R+/+, D3R+/- and D3R -/- naïve (n = 8/10 per group). For 





























































experimental groups: D3R+/+ treated with vehicle, D3R+/+ treated with Ro 15-4513, D3R-/-  
treated with vehicle and D3R-/- treated with Ro 15-4513 (n = 8/10 per group).
In another set of experiments, D3R+/+ and D3R-/- were randomly allocated to 3 experimental 
groups (n= 8/13 per group): D3R+/+ treated with SB277011A for 7 days before SB 277011A 
plus Ro 15-4513 during the DID procedure; D3R+/+ treated with Vehicle for 7 days before 
Vehicle plus Ro 15-4513 during the DID procedure and D3R+/+ treated with Vehicle for 7 
days before Vehicle plus Vehicle during the DID procedure. SB 277011A and Ro 15-4513 
were i.p. injected, respectively 1h and 15 minutes before DID. On day 4, animals were 
sacrificed 1 h after ethanol-drinking procedure and the brain tissues were taken. 
2.6. Intra-accumbens administrations
Ro 15-4513 and furosemide (Tocris) were dissolved in 10% dimethyl sulfoxide and 90% 
synthetic cerebrospinal fluid (CSF) [15, 19]. Cannulas were implanted as previously 
described (11). After anesthesia with tiletamine + zolazepam (60 mg/kg) and 
medetomidine (40 μg/kg), mice were implanted with a 26-gauge guide cannula into the 
NAc (coordinates from Bregma: anterior-posterior = + 1.42 mm, latero-lateral ± 0.75 mm to 
a depth of 4.1 mm). The cannulas were fixed to the skull with acrylic dental cement 
(RelyX™ Unicem). After 6–8 days recovery, drugs (10 nmol/mouse ) were bilaterally 
injected in a final volume of 1 μl over 1 min through infusion cannulas connected to a 
Hamilton microsyringe by a polyethylene tube. Ro 15-4513 was injected 15 minutes before 
the DID, whereas furosemide was injected 5 min before Ro 15-4513. Animals were 
handled gently to minimize stress during infusion. After the infusion procedure, the needle 
was left in place for another minute to allow diffusion. In the DID paradigm, mice were 





























































4513, D3R-/- / furosemide + Ro 15-4513. After behavioral testing, a solution of 4% 
methylene blue was infused for histological localization of infusion cannulas.
2.7. Electrophysiology
For the preparation of brain slices, we followed the protocol described by Scala et al. [32], 
with minor modifications. The detailed protocol is reported in Supplemental Information 
section. The electrophysiological recordings were analyzed using the Clampfit 10.7 
software (Molecular Devices). A template was constructed using the “Event 
detection/create template” function, as described in [33], then, miniature inhibitory 
postsynaptic currents (mIPSCs) were detected using the “Event detection/template 
search” function. All the waveforms detected during a single recording using template 
analysis were averaged and amplitude, rise time and decay time calculated. 
2.8. Statistical analysis
Data are expressed as means ± standard deviation (SD). Statistical significance was 
assessed with the Student’s t test (when used, paired-t test has been indicated in the text), 
one- or two-way analysis of variance (ANOVA) and post hoc Newman-Keuls. The level of 






























































3.1. Alcohol intake and GABAA α6 subunit expression
We previously reported that D3R-/- mice have low ethanol intake [15] and exhibit higher 
basal expression of GABAA α6 in the ventral striatum [19]. Here, we assessed whether a 
link exists between alcohol consumption and GABAA α6 subunit expression in the NAc. 
D3R-/- exhibited about 5-fold higher basal mRNA expression of α6 subunit as compared 
with D3R+/+in the NAc [main effect of genotype F (2, 14) = 9.447, P<0.01; post hoc: 
P<0.01], but not in the prefrontal cortex (PFC), while other relevant GABAA subunits were 
not changed (Fig.1 A-B). Based on these data, we compared D3R+/+, heterozygous D3R+/- 
and homozygous D3R-/- in the drinking-in-the-dark (DID) paradigm. As shown in Fig. 1C, 
D3R+/+exhibited obvious ethanol preference in DID paradigm on day 1, 2 and 3, whereas 
D3R-/- had significantly lower ethanol intake [main effect of day: F (3, 60) = 40.58, P<0.01; 
main effect of genotype F (2, 20) = 7.812, P<0.01; post hoc: P<0.01 and P<0.05]. D3R+/- 
showed alcohol intake similar to D3R+/+and, consistently, a low α6 expression in the NAc 
(Fig. 1D).  The lack of difference in ethanol intake on day 4 might be linked to the 4h-time 
window used instead of a 2h-time window (see Methods). Overall, these data suggest that 
there is a link between α6 mRNA expression and alcohol intake such that the high level of 
GABAA α6 subunit expression in the NAc is associated to reduced alcohol consumption. 
To precisely assess the spatial expression of α6 subunit in the brain of D3R+/+and D3R-/-, 
we carried out in situ hybridization (ISH) experiments and analyzed the results in a blinded 
manner. These experiments confirmed that, while heavily enriched in the cerebellar 
granule cell layer, significant α6 expression in the forebrain of D3R-/- occurred specifically in 
the NAc [P<0.05], being very low in the other examined brain areas (Fig. 2 A-D, Tab. S1-





























































D3R-/- (Tab. S1-S2). Data obtained by ISH confirmed the qPCR data (Fig. 1 A-B). 
Autoradiography following incubation with a high 15 nM concentration of [3H]Ro15-4513 
showed a statistically significant increase of [3H]Ro15-4513 binding in the NAc [P<0.05] 
(Fig. 2 E-F). Ro 15-4513 binds at α6/4β3δ-type GABAA receptors with high affinity (KD ≈ 10 
nM) [21, 34], consistent with an increased expression of α6/4β3δ-type GABAA receptors in 
the NAc.
3.2. Alcohol antagonist Ro 15-4513 increased ethanol consumption in mice expressing 
GABAA α6 in NAc
Ro15-4513 was earlier named “alcohol antagonist” [35], because, in some studies, it 
inhibited alcohol intoxication, preference and self-administration in wild type rodents [31, 
36]. Therefore, based on ISH and [3H]Ro15-4513 binding data, we tested the hypothesis 
that Ro 15-4513 differently affects ethanol intake in mice expressing different levels of α6 
in the NAc. As shown in Fig. 3 A, systemic administration of Ro 15-4513 decreased 
voluntary ethanol intake in D3R+/+ [main effect of day F (3, 63) = 55.62, P<0.01; main effect 
of treatment F (1, 21) = 7.198, P<0.05; post hoc: P<0.05], but increased voluntary ethanol 
intake in D3R-/- (Fig. 3 B) [main effect of day F (3, 39) = 34.87, P<0.01; main effect of 
treatment F (1, 13) = 9.384, P<0.01; post hoc: P<0.05]. Worthy of note, D3R-/-, which 
normally show low preference for alcohol [15], following Ro 15-4513–treatment reached a 
level of ethanol consumption similar to that of D3R+/+. To gain stronger evidence of the 
specific role of D3R-dependent expression of α6 GABAA subunit in the NAc, we tested 
D3R-/- mice in the DID after intra-NAc administration of Ro 15-4513, with or without 
furosemide, an α6-GABAA receptor antagonist [37]. As shown in Fig. 3 C, intra-NAc 
administration of Ro 15-4513 increased voluntary ethanol intake in D3R-/- [main effect of 





























































= 3.297 P<0.05, post hoc: P<0.05, P<0.01 and  P<0.001 vs vehicle]; the effect of Ro 15-
4513 injected in this brain area was blocked by pretreatment with furosemide [main effect 
of treatment F (2, 13) = 22.31, P<0.001; main effect of days X treatment interaction F (6, 
39) = 3.297, post hoc: P<0.001 vs furosemide+Ro 15-4513] (Fig. 3D). This result confirms 
that the increased expression of α6-GABAAR in the NAc has a key role in modulating the 
paradoxical effect of Ro 15-4513 in D3R-/- mice, ruling out potential off target and/or non-
specific effects of Ro 15-4513 (on other brain areas, because of intraNAc injection, and on 
other GABAA receptor isoforms, because of furosemide antagonism). Thus, the 
paradoxical response to Ro 15-4513 seen in D3R-/- is related to increased expression of -
GABAAR in the NAc, which also accounts for the low ethanol consumption observed in 
these mice, as mentioned above.  
Changes of GABAAR function induced by alterations in dopaminergic transmission may 
have clinical relevance, because a number of DR ligands are currently used to treat 
different neuropsychiatric disorders [38]. In this respect, consistent with data obtained in 
D3R-/- mice, we previously reported that chronic treatment with the selective D3R 
antagonist SB 277011A increases α6 expression in the ventral striatum and accelerates 
the appearance of tolerance to the anxiolytic effect of diazepam [19]. Here, to assess the 
functional relevance of the D3R/α6-GABAAR cross-talk, we treated D3R+/+with SB 277011A 
for 7 days, (10 mg/kg i.p. as done in [19]) before testing in the DID paradigm. As shown in 
Fig. 3D, pretreatment of D3R+/+ with SB 277011A for 7 days, which increased the 
expression of α6-GABAAR in the NAc (Figure S1), induced a paradoxical effect of Ro 15-
4513 on alcohol intake, similar to D3R-/- [main effect of days F (3, 108) = 31.59, P<0.001; 
main effect of treatment F (2, 36) = 19.34, post hoc: P<0.05, P<0.001 vs vehicle]. These 
data indicate that treatment with a D3R antagonist, sufficient to change the expression of 





























































3.3. D3R-/- mice exhibited Ro 15-4513-driven decrease of mIPSC amplitude in Medium 
Spiny Neurons 
To test the hypothesis that α6 subunit expression in the NAc shell, as seen in D3R-/- mice, 
modifies inhibitory transmission, we performed whole-cell patch-clamp recordings on 
GABAergic MSNs, which represent >95% of the cell population in this brain region, and 
recorded miniature inhibitory postsynaptic currents (mIPSCs). Analysis of the peak 
amplitudes of mIPSCs revealed a significant increase in D3R-/- compared to D3R+/+(Fig. 4; 
A-D; 38.58 ± 3.35 pA, n = 19 versus 29.51 ± 2.96 pA, n = 16; P<0.05). In contrast, there 
was no significant difference in mIPSC frequency (D3R-/-: 1.98 ± 0.30 Hz, D3R+/+: 1.77 ± 
0.26 ms) and mIPSC kinetics (Fig. 4 G, H; rise time, D3R-/-: 0.72 ± 0.06 ms; D3R+/+: 0.72 ± 
0.06 ms; decay time, D3R-/-: 16.96 ± 1.10 ms; D3R+/+: 16.14 ± 1.31 ms). Next, we tested 
the effects of Ro 15-4513 on mIPSCs in MSNs from D3R+/+and D3R-/-. Based on ISH and 
qPCR data, indicating that α6-GABAARs in the NAc are scarce in naïve D3R+/+mice and 
given the opposite effect of Ro 15-4513 treatment on ethanol intake observed in D3R-/- 
mice, we expected that Ro 15-4513 would have differential effects on mIPSCs. For this in 
vitro experiment we selected the 0.3 μM Ro 15-4513 concentration, because it completely 
antagonizes ethanol enhancement of α4β3δ-type GABAAR current [21]. As shown in Fig. 
4, bath application of 0.3 μM Ro 15-4513 did not significantly alter the frequency, rise time, 
decay time and amplitude of mIPSCs in D3R+/+ (n = 16; paired t test), but induced a 
significant reduction of amplitude in the NAc of D3R-/- (Figure 3; B-F; 38.58 ± 3.35 pA, 
versus 31.93± 3.03 pA, n = 19 P<0.05; paired t test) while frequency, rise time and decay 
time were not affected. These results suggest that the activity of α6-GABAAR in D3R-/- 
influences inhibitory synaptic transmission of MSN within NAc shell, possibly because α6 
expression, higher than in D3R+/+, is sufficient to generate a population of heteromeric 






























































We found that increased expression of α6 GABAA subunit, induced by D3R deletion or 
pharmacological blockade, is associated to reduced alcohol intake and increased GABA 
inhibition in the NAc. We revealed GABAA α6 activity by using Ro 15-4513, both in terms 
of behavior (ethanol intake) as well as of neuronal excitability (electrophysiology) a GABAA 
ligand that exerts α6-dependent effects. Ro 15-4513 is considered a high affinity α6-
GABAAR ligand, since its binding is obvious in a α6 rich brain structure, such as the 
cerebellum, while it is hardly detectable in the very same structure in α6 null mice [26]. 
We previously reported that alcohol sensitization is linked to increased D3R expression 
induced by ethanol intake and is associated with the activation of RACK1/BDNF pathway. 
In fact, selective blockade of the TrkB, the receptor for BDNF, reverses stable intake of 
ethanol in WT mice and decreases D3R expression levels in their striatum, while it results 
ineffective in D3R-/- mice [15]. 
The α6 subunit came to the attention of the alcohol addiction studies following the 
identification of the R100Q mutation in the Sardinian non-ethanol-preferring rat line, 
suggesting a possible involvement of the GABAAR containing α6 subunit in the genetic 
predisposition to alcohol preference [10]. This mutation is associated with hypersensitivity 
to motor-impairing effects of ethanol and tonic inhibitory currents mediated by α6βδ-type 
GABAAR in cerebellar granule cells [8, 13]. Worthy of note, this mutation strongly 
increases diazepam effect on GABA-evoked currents [11]. Consistently, a model where 
the amino acidic residue at position 100 affects ethanol sensitivity in the GABAARs is part 
of the benzodiazepine ligand-binding pocket on the α6-subunit [19, 40]. Other studies have 
also described α6 polymorphisms that correlate to alcohol dependence in humans [41, 42]. 





























































GABAA α6 subunit expression in the ventral striatum [16], a brain structure involved in 
voluntary ethanol intake, provides a tool to study how the increased expression of α6 
subunit-containing receptors may affect alcohol intake. Indeed, some studies have 
evaluated the contribution of other GABAAR subunits, such as α4 and δ, but no data are 
available on the role of NAc GABAA α6 subunit in alcohol intake; this latter has only been 
studied for its involvement in the motor incoordination associated to alcohol, given its 
abundant localization in cerebellum granule cells.
Several studies, in the last two decades, have tried to elucidate how the subunit 
composition of different GABAARs determines their electrophysiological and 
pharmacological features (inhibitory currents, ligand binding), or, at the organism level, the 
animal behavior (anxiety, addiction, response to anxiolytics). While most studies have 
dealt with recombinant systems, such as Xenopus laevis oocytes injected either with 
cRNA coding for the different subunits [9, 21] or with cRNA coding for concatenated 
subunits [43], no studies had the opportunity to examine native systems, i.e. animals 
spontaneously and stably expressing specific subunits in defined CNS structures. 
Polymorphisms of α6 subunit have been found to be associated both to anxiety-related 
traits [44] and to benzodiazepine sensitivity in humans [45]. It is not yet known whether 
increased expression of α6 subunit containing GABAAR isoforms in brain areas that 
normally express negligible amounts of α6 produces different responses to GABA (i.e. 
different inhibitory currents) and/or to exogenous modulators. This might be due to the lack 
of in vivo systems with significant changes in α6 expression. Early studies with α6 subunit 
knockout mice [26, 46] remained inconclusive as it was later discovered that the knockout 
construct affected the expression of neighboring subunits in the GABAA gene cluster [47]. 
We took advantage of Ro 15-4513, because it has been proposed to compete with ethanol 
within a binding pocket involving α6 [23]. We expected a different effect of Ro 15-4513 in 





























































Indeed, we found an opposite effect of Ro 15-4513 in the two groups; in D3R+/+, the 
systemic administration of Ro 15-4513 reduced ethanol intake, presumably as a result of 
its action as a negative allosteric modulator in multiple GABAARs [21], where it would 
behave as an “ethanol antagonist” [23, 48].  Conversely, in D3R-/-, Ro 15-4513 
paradoxically increased ethanol intake, a surprising finding that might be explained in 
terms of differential modulation of the GABAAR containing α6 subunit by Ro 15-4513. 
These data were confirmed and validated by intra-NAc injection experiments, where the 
local administration of furosemide, a selective α6-GABAA receptor antagonist [37], 
completely blocked the effect of Ro 15-4513. 
The antagonism between Ro 15-4513 and ethanol might be more at the functional level, 
rather than at the binding level. While the reported affinity of Ro 15-4513 for α4 and α6 
containing GABAAR is quite similar in the nanomolar range [9, 21, 23], the effect on the 
GABA-dependent currents in cells expressing exclusively α4 or α6 subunits is not clear 
and might be quite different. This is consistent with the paradoxical activation of neurons 
by gaboxadol in a transgenic Thy1α6 mouse line, ectopically expressing the GABAAR α6 
subunit gene under the Thy-1.2 promoter [20]. We directly address this issue by 
measuring MSN mIPSCs in the NAc and their sensitivity to Ro 15-4513. Based on the 
above premises, we hypothesized that a change in GABAA α6 subunit expression would 
increase spontaneous mIPSCs and that Ro 15-4513 would inhibit mIPSCs in MSN from 
D3R-/-, robustly expressing α6, whereas it would be ineffective in α6-deficient MSNs from 
D3R+/+. The electrophysiological analysis of MSNs revealed a significant increase in 
mIPSC amplitude in D3R-/-, which expressed GABAAR containing α6 subunit in NAc, 
compared to D3R+/+. Accordingly perfusion with Ro 15-4513 induced a significant reduction 
of amplitude in the NAc of D3R-/-, but was ineffective in D3R+/+. This latter observation 
clearly indicates that the modulation of the GABAAR channel by Ro 15-4513 depends on 





























































drug on ethanol intake in D3R+/+and D3R-/-. To precisely assess the spatial expression of 
α6 subunit in the brain of D3R+/+and D3R-/-, we carried out in situ hybridization (ISH) 
experiments. The systematic assessment of α6 expression in the CNS by ISH confirmed  
qPCR results, indicating that α6 expression in D3R-/- was restricted to a limited brain area, 
corresponding to the NAc. These results were reinforced also by autoradiography data 
obtained with [3H]Ro 15-4513. The fact that genetic or pharmacological manipulation of 
D3R induced changes in the GABAAR α6 subunit expression specifically in the NAc  is 
consistent with the leaving relatively unchanged other brain areas is not so surprisingly, 
considering that, at variance with D2R, restricted expression of D3R in this brain region t 
same structures where we observe increased α6 expression [49]. To the best of our 
knowledge, it is not known in detail how D3R controls GABAAR subunit mRNA expression; 
however, other studies have shown dynamic D3R-dependent down-regulation of 
GABAergic control over lateral/basolateral amygdala neurons [50], NAc [51] and 
hippocampus [52]. A direct dynamic interplay between metabotropic DA receptors and 
other ionotropic receptors in plasma membrane has been documented by single-molecule 
detection imaging and electrophysiology in live hippocampal neurons [53]. Furthermore, 
cell signaling downstream of D3R affects GABAARs in the NAc [51], but numerous other 
complex mechanisms may impact GABAARs trafficking [54] and deserve further studies to 
be elucidated. Finally, because these changes in GABAAR function can be related to 
dopaminergic transmission, they may assume further relevance in clinical situations, such 
as schizophrenia and Parkinson’s disease, where D3R are chronically blocked or 
stimulated by drug-treatments [38]. 
In conclusion, these data indicate that α6-containing GABAARs in the NAc play an 
important role in controlling alcohol intake by increasing GABAergic-inhibition in the MSNs. 





























































blockade, the interplay between DAergic and GABAergic transmission may present a 
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Figure 1. Alcohol intake and D3R-dependent GABAA α6 subunit mRNA expression in the 
NAc. A and B, GABAAR α1, α2, α4, α6, γ2 and δ subunits mRNA expression in the 
nucleus accumbens (NAc) and in the prefrontal cortex (PFC) of wild type (D3R+/+) and D3R 
null mice (D3R-/-). Abundance of transcripts was assessed by qPCR (primer sequences are 
reported in Tab. S3). C and D, ethanol intake (in the drinking in the dark paradigm, DID) 
and 6 expression in wild type (D3R+/+) heterozygous (D3R+/-) and null mice (D3R-/-). DID 
was measured for 4 days, in mice with limited access (2h/day for 3 days and 4h the 4th 
day) to ethanol solution (20%). Abundance of transcripts in the NAc was assessed by 
qPCR after DID; expression level is given as mean fold changes relative to controls.  
*P<0.05, **P<0.01 vs. the corresponding control (D3R+/+,); one- or two-way ANOVA and 
Newman–Keuls post hoc test.  Each experimental group included 8-10 mice.
Figure 2. Expression of 6 GABAA subunit mRNA and [3H]-Ro 15-4513 binding in the NAc 
and Cerebellum of D3R+/+ and D3R-/- mice. A, B, C and D In situ hybridization (ISH) 
detection of 6; E, F, G and H, [3H]-Ro 15-4513 autoradiography. A, C, E and G show 
representative images.  B, D, F and H show average optical density, (expressed in 
arbitrary units); n=6-8 per group. *P < 0.05 vs. D3R+/+, unpaired t test.
Figure 3. Opposite effect of RO 15-4513 on alcohol intake, in D3R+/+ and D3R-/- (drink in 
the dark paradigm, DID). A and B, ethanol intake in D3R+/+ and D3R-/- intraperitoneally (i.p.) 
treated with vehicle (VEH) or Ro 15-4513 (5 mg/kg); C, ethanol intake in D3R-/- locally 
injected into the NAc with VEH, Ro 15-4513 (10 nmol/mouse) or furosemide (10 





























































selective D3R antagonist, SB 277011A for 7 days (10 mg/kg, i.p.) plus Ro 15-4513 (5 
mg/kg, i.p.) over DID paradigm. 
Each experimental group included 8-13 mice. *P<0.05, **P<0.01, ***P<0.001 vs. vehicle 
(VEH). One- or two- way ANOVA and Newman–Keuls post hoc test.
Figure 4. NAc medium spiny neurons from D3R-/- mice exhibited increased GABAA 
inhibitory currents sensitive to Ro 15-4513. A and B, representative traces showing mIPSC 
recordings in slice from D3R+/+  and D3R-/- mice before and after treatment with Ro 15-4513 
(0.3 µM; in red). C, analysis of the peak amplitudes of mIPSCs; notice an increase in D3R-/- 
compared to D3R+/+ and a decrease following Ro 15-4513 application in D3R-/- only. D-F, 
cumulative frequency distributions for mIPSC amplitude in the experimental conditions 
shown in A and B. G-I, analysis of mIPSC frequency, rise time and decay time. 
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Dopaminergic-GABAergic interplay and alcohol binge drinking
Supplementary Information
Table S1. In situ hybridization (ISH) signals for GABAA ??1, ??2, ??4, ??6, γ2 and δ subunit 
mRNA in the prefrontal cortex from D3R+/+ and D3R-/- mice.
GABAA subunit ISH signal (D3R-/- over D3R+/+ ratio)
α1 0.92  0.02
α2 1.10  0.11
α4 0.80  0.07
α6 1.15  0.13
γ2 0.89  0.30
δ   0.83  0.17
Table S2. In situ hybridization (ISH) signals for GABAA ??1, ??2, ??4, ??6, γ2 and δ subunit 
mRNA in the hippocampus from D3R+/+ and D3R-/- mice.
GABAA subunit ISH signal (D3R -/- over D3R +/+ ratio)
α1 0.91  0.09
α2 1.19  0.13
α4 1.07  0.03
α6 1.20  0.10
γ2 0.96  0.26
δ   0.85  0.16
Table S3. Primers for Real-Time PCR















Figure S1. Pharmacological blockade of D3R counteracts alcohol intake and induced 
overexpression of GABAA 6 subunit in the NAc of D3R+/+. A and B, ethanol intake (DID) and 
6 expression in D3R+/+ treated with vehicle (VEH) or the selective D3R antagonist, SB 
277011A (10 mg/kg, i.p.) for 7 days. Each experimental group included 8-13 mice. *P<0.05, 
***P<0.001 vs. VEH; two-way ANOVA and Newman–Keuls post hoc test.  
Material and Methods
In situ hybridization
Air-dried slides were fixed in ice-cold 4% paraformaldehyde for 5 min. The sections were 
washed in 1 PBS at room temperature for 5 min, dehydrated in 70% ethanol for 5 min and 
stored in 95% ethanol at 4 °C until used. The antisense DNA oligonucleotide probe (Oligomer 
Oy, Helsinki, Finland) sequences were as follows: α6, 5’-CAG TCT CTC ATC AGT CCA AGT 
CAT-3’;  was complementary to the mouse GABAAR subunit mRNA sequence. Poly[35S]dATP 
(PerkinElmer Life and Analytical Sciences, Boston, MA) tails were added to the 3’-ends of the 
probes by deoxynucleotidyl transferase (Promega Corporation, Madison, WI). Unincorporated 
nucleotides were removed by Illustra ProbeQuant G-50 Micro Columns (Amersham 
Biosciences, Buckinghamshire, UK). Labelling efficiency (360,000 cpm/μl) was determined by 
a scintillation counter. The labeled probe was diluted to 0.06 fmol/μl of hybridization buffer 
consisting of 50% formamide and 10% dextran sulfate in 4X Saline Sodium Citrate (SSC). 
Nonspecific controls for the antisense probes were produced by adding 100-fold excess of 
unlabeled probes. The hybridization occurred under glass Menzel-Gläser coverslips (Thermo 
Fisher Scientific, Boston, MA) overnight at 42 °C. Finally, the slides were washed in 1X SSC 
at room temperature for 10 min, in 1X SSC at 55°C for 30 min, and 1X SSC, 0.1X SSC, 70% 
EtOH and 95% EtOH at room temperature for 1 min each. The slides were then air-dried and 
exposed with plastic [14C]-radioactivity standards (GE Healthcare) to BioMax MR films 
(Eastman Kodak Company, Rochester, NY). Films were scanned (Epson expression 1680 
Pro). Images were imported into the FIJI version of the free image processing software 
ImageJ. The [14C]-standards were exposed simultaneously with the brain sections as the 
reference. The hybridization values were converted to arbitrary optical density units. Non-
specific signal was subtracted to obtain the specific signal. All measurements were analyzed 
in blind.
[3H]Ro 15-4513 autoradiography 
Slides were pre-incubated in ice-cold 50 mM Tris–HCl buffer, pH 7.4, containing 120 mM 
NaCl for 15 min. The final incubation for basal [3H]Ro 15-4513 binding was performed in the 
pre-incubation buffer containing 15 nM [3H]Ro 15-4513 (23 Ci/mmol, PerkinElmer Life and 
Analytical Sciences) at 4 °C for 1 h. This high ligand concentration was aimed at estimating 
the receptor number rather than affinity. The non-specific binding was determined in the 
presence of 10 μM flumazenil. The sections were then washed in ice-cold pre-incubation 
buffer twice for 1 min, dipped in ice-cold distilled water, air-dried at room temperature and 
exposed with [3H]-plastic standards for 12  weeks (GE Healthcare) to Biomax MR films 
(Eastman Kodak). The films were scanned (Epson expression 1680 Pro) and binding density 
was expressed as arbitrary optical density units (FIJI IMAGE-J). The [3H]-standards were 
exposed simultaneously with the sections as the reference. Non-specific binding was 
subtracted to obtain the specific binding values. All data were analyzed in blind.
Electrophysiology
Animals were sacrificed by cervical dislocation. Brains were rapidly removed and placed in 
ice-cold cutting solution containing (in mM): TRIS-HCl 72, TRIZMA base 18, NaH2PO4 1.2, 
NaHCO3 30, KCl 2.5, glucose 25, HEPES 20, MgSO4 10, Na-pyruvate 3, ascorbic acid 5, 
CaCl2 0.5, sucrose 20. Slices (300 μm thick) were cut on a vibratome (VT1200S; Leica 
Microsystems, Germany) and immediately transferred to an incubation chamber held at 32°C 
and filled with a recovery solution containing (in mM): TRIS-HCl 72, TRIZMA base 18, 
NaH2PO4 1.2, NaHCO3 25, KCl 2.5, glucose 25, HEPES 20, MgSO4 10, Na-pyruvate 3, 
ascorbic acid 5, CaCl2 0.5, sucrose 20. After 30 min, slices were transferred to a second 
incubation chamber held at 32°C and filled with artificial cerebrospinal fluid (aCSF) containing 
(in mM): NaCl 124, KCl 3.2, NaH2PO4 1.2, MgCl2 1, CaCl2 2, NaHCO3 26, and glucose 10, pH 
7.4. During incubations, the chambers were continuously bubbled with 95% O2/5% CO2. 
Slices were equilibrated at room temperature for at least 45 min. Slices were then transferred 
to a submerged recording chamber constantly perfused with heated aCSF (32°C) and 
bubbled with 95% O2/5% CO2. Medium spiny neurons (MSNs) within the NAc shell subregion 
were identified with a 40X water-immersion objective on an upright microscope equipped with 
differential interface contrast optics under infrared illumination (BX5IWI, Olympus, Center 
Valley, PA) and video observation. Electrodes were made from borosilicate glass 
micropipettes (Warner Instruments, Hamden, CT) prepared with a P-97 Flaming-Brown 
micropipette puller (Sutter Instruments, Novato, CA). Patch pipettes had a resistance of 4-6 
MΩ when filled with an internal solution containing (in mM): CsCl 135, HEPES 10, EGTA 1.1, 
CaCl2 0.1; Mg-ATP 2.5, Na-GTP 0.25, phosphocreatine 5, pH 7.2. After establishing a 
gigaseal, the patch was broken by applying negative pressure to achieve a whole-cell 
configuration. A series resistance lower than 15 MΩ was considered acceptable, and 
monitored constantly throughout the entire recording. Neurons were held at -70 mV. 
Tetrodotoxin (TTX, 0.5 μM, Tocris),  D-(-)-2-Amino-5-phosphonopentanoic acid (D-AP5, 50 
μM, Tocris) and 2,3-Dioxo-6-nitro-1,2,3,4-tetrahydrobenzo[f]quinoxaline-7-sulfonamide 
(NBQX, 10 μM, Tocris) were applied to the bath to block action potential-mediated 
neurotransmitter release, NMDA and AMPA receptors, respectively. Ro 15-4513 (0.3 μM) was 
applied in the bath after 5-7 min of TTX, APV and NBQX perfusion. All recordings were 
carried out at least 10 min after application of any drug to the bath. Recordings were 
performed using a Multiclamp 700B/Digidata 1550A system (Molecular Devices, Sunnyvale, 
CA) and digitized at a 10,000 Hz sampling frequency.
